The Rest Is Money 132. Why Britain Isn’t A “Science Superpower”
28 snips
Jan 23, 2025 
In a compelling discussion, Sir Paul Nurse, a Nobel Prize-winning biochemist and director of the Francis Crick Institute, unpacks the UK’s scientific landscape. He critiques the country’s struggles to attract talent, hindered by high visa costs and poor funding support. Nurse contrasts the UK's pure discovery strengths with its failures in commercial application, while advocating for systemic reforms. He also shares a heartfelt personal journey about discovering his biological roots and reflects on the interplay between AI and human creativity in advancing science.
AI Snips
Chapters
Transcript
Episode notes
Inaccurate Data
- Inaccurate data from the Office for National Statistics (ONS) misrepresented UK science spending.
- The ONS significantly underestimated business R&D spending, impacting government policy.
Low Government Spending
- The UK government's science spending is low compared to other OECD countries.
- At 0.15% of GDP, this is significantly below the OECD average and ranks the UK 18th out of 33 nations.
ARIA's Approach
- The Advanced Research and Invention Agency (ARIA) models a start-up approach, focusing on potentially commercially valuable research areas.
- While too early to assess its long-term success, its approach and protected status offer valuable insights.